French biotech company TxCell (Euronext Paris: TXCL) has named five new vice presidents across segments in a bid to strengthen its management team.
The company named Nathalie Belmonte as VP research operations, Liliane Guilmin as VP project management and Pierre Heimendinger as VP process development.
Further, Catherine Mathis is appointed VP Regulatory Affairs and Maud Bouvier as VP Business Development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze